NCT01365520View on ClinicalTrials.gov

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Congenital Bleeding DisorderHaemophilia A
Interventions
DRUG

turoctocog alfa

A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.

Trial Locations (3)

50400

Novo Nordisk Investigational Site, Kuala Lumpur

NW3 2QG

Novo Nordisk Investigational Site, London

SE1 7EH

Novo Nordisk Investigational Site, London

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY